Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center

Inflammatory Bowel Diseases

Volumn 18, Issue 1, 2012, Pages 10-16

  Cohen, Russell D ^a   Lewis, Jeffrey R ^a   Turner, Hannah ^a   Harrell, Laura E ^a   Hanauer, Stephen B ^a   Rubin, David T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

adalimumab; anti TNF therapy; Crohn's disease; inflammatory bowel disease

Indexed keywords

ADALIMUMAB;

ADOLESCENT; ADULT; ARTICLE; COLON DISEASE; CROHN DISEASE; DISEASE DURATION; DRUG DOSE ESCALATION; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT REFERRAL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; SURVIVAL; TERTIARY HEALTH CARE; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 83555172398     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21707     Document Type: Article

References (33)

1. Loftus EV Jr,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504-1517. (Pubitemid 38649869)
2. Van Deventer SJ,. Tumour necrosis factor and Crohn's disease. Gut. 1997; 40: 443-448. (Pubitemid 27204920)
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549. (Pubitemid 34621118)
4. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004; 2: 912-920. (Pubitemid 39335798)
5. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
6. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340: 1398-1405. (Pubitemid 29205403)
7. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885. (Pubitemid 38252535)
8. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601-608. (Pubitemid 36204954)
9. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323-333.
10. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239. (Pubitemid 47300424)
11. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65. (Pubitemid 46108762)
12. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146: 829-838. (Pubitemid 351650483)
13. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004; 99: 1984-1989. (Pubitemid 39421244)
14. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009; 104: 1170-1179.
15. Hanauer SB,. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003; 17: 131-137.
16. Ranson JH, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet. 1974; 139: 69-81.
17. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996; 38: 905-910. (Pubitemid 26231777)
18. Rowe FA, Walker JH, Karp LC, et al. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol. 2000; 95: 2000-2008.
19. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007; 13: 123-128. (Pubitemid 46806219)
20. Laharie D, Salzmann M, Boubekeur H, et al. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol. 2005; 29: 145-149. (Pubitemid 40380162)
21. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006; 55: 598-606. (Pubitemid 44436647)
22. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004; 63: 665-670. (Pubitemid 38658395)
23. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol. 2009; 104: 3042-3049.
24. Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol. 2009; 104: 2566-2571.
25. Louis E, Peeters M, Franchimont D, et al. Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour? Clin Exp Immunol. 2000; 119: 64-68. (Pubitemid 30064592)
26. Steinhardt HJ, Loeschke K, Kasper H, et al. European Cooperative Crohn's Disease Study (ECCDS): clinical features and natural history. Digestion. 1985; 31: 97-108. (Pubitemid 15100650)
27. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002; 122: 875-880. (Pubitemid 34267269)
28. Loftus EV Jr, Schoenfeld P, Sandborn WJ,. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002; 16: 51-60. (Pubitemid 34123864)
29. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009; 137: 1628-1640.
30. Swaminath A, Ullman T, Rosen M, et al. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients. Aliment Pharmacol Ther. 2009; 29: 273-278.
31. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-238. (Pubitemid 47080387)
32. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005; 353: 1912-1925. (Pubitemid 41565956)
33. Rankin GB, Watts HD, Melnyk CS, et al. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979; 77: 914-920. (Pubitemid 9242053)